Concepedia

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mıkhael, Ravi Vij, Brigitte Pegourié, Lofti Benboubker, Thierry Façon, Martine Amiot, Philippe Moreau,

Blood · 2017 · 527 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).

References

23

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

, , +12

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

, , +14

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

, , +17

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

, , +17

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

S. Vincent Rajkumar, Jean‐Luc Harousseau, Brian G.M. Durie et al. · Blood · 2011 · 1K citations · Full text

, , +13